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Abstract: 
The purine ATP has a prominent regulatory role in CNS function and pathology due to its 
actions on glial cells - microglia, astrocytes and oligodendrocytes. ATP serves as an 
apparently ubiquitous ‘gliotransmitter’ that is released by astrocytes and other cells to 
activate purine receptors on neighbouring cells. In pathology, the release of ATP mediates 
both tissue damage and repair by its direct effects on glial cell integrity and survival. The 
actions of ATP on glia are mediated via a wide range of receptors, broadly divided into 
ionotropic P2X and metabotropic (G-protein coupled receptors (GPCR) P2Y receptors, of 
which there are multiple subtypes (P2X1-P2X7 and P2Y1-P2Y14). ATP-mediated interactions 
between astrocytes and microglia are at the centre of immune responses in the CNS, with 
prominent roles for the P2X4, P2X7, P2Y1, P2Y6 and P2Y12 receptor subtypes. In 
oligodendrocytes, P2X7 and P2Y1 receptor subtypes have a bipartite function in respectively 
mediating oligodendrocyte destruction and protection. Purine receptors mediate glial 
pathology, with prominent roles in ischemia, neuroinflammation, Multiple Scelerosis, 
neuropathic pain and traumatic injury. Notably, glial ATP signalling may be altered with 
ageing and is implicated in impaired myelination and immunity in Alzheimer’s disease. 
Hence, glial purine receptors provide potential therapeutic targets in multiple 
neuropathologies, but the ‘Jeckyll and Hyde’ nature of purine signalling underscores the 
importance of further research and a comprehensive understanding of the roles of the 
different purine receptors in mediating tissue damage and repair. 
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BACKGROUND 
The main types of glia in the central nervous system (CNS) are astrocytes, 
oligodendrocytes and microglia, each of which are specialised to perform specific functions 
to enable CNS function and are integral to all neuropathologies (1). Astrocytes are 
multifunctional cells with essential neuron supporting functions, including homeostasis, 
metabolic support, neurovascular coupling and forming the neuroprotective scar following 
injury. Furthermore, astrocytes encompass synapses and play a critical role in 
neurotransmitter uptake and are implicated in synaptic transmission as part of the tripartite 
synapse (2). Oligodendrocytes are responsible for myelination, which is essential for rapid 
axonal communication and higher cognitive function (3, 4). Microglia have a macrophage 
function and provide the innate immunity in the CNS (5). A universal property of glial cells is 
their responsiveness to ATP through their expression of multiple purine receptors (6). 
Purinoceptors mediate the characteristic responses of glia to CNS insults – astrocyte 
reactivity, microglial activation and oligodendrocyte/myelin loss. Hence, glial purinoceptors 
are potential therapeutic targets in multiple CNS disease states.  
 
GLIAL PURINE RECEPTORS 
Purine receptors are broadly divided into adenosine (P1) and ATP (P2) receptors, and 
there is evidence for expression of both groups in different glial cells (6).  P2 receptors (P2R) 
are further divided into ionotropic P2XR and G-protein coupled metabotropic P2YR, which 
can be distinguished by a range of agonists and antagonists (7). There are seven P2XR 
subunits (P2X1-7), which assemble as trimers to form homomeric and heteromeric receptors 
with a diverse range of properties (8). P2XR are cationic ligand-gated channels permeable to 
Na+, K+ and Ca2+, and most are activated at low concentrations of ATP, with EC50 of 1–10 M, 
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whereas P2X7R are activated at high concentrations of ATP, in the 0.1-1 mM range, and are 
capable of pore formation, resulting in sustained influx of Ca2+ (7). There are eight subtypes 
of P2YR, which exhibit different preferences for ATP/ADP (P2Y1, P2Y11, P2Y12, and P2Y13), 
ATP/UTP (P2Y2), UTP (P2Y4), UDP (P2Y6) or UDP-glucose and other nucleotide sugars (P2Y14) 
(7). P2YR may assemble as homodimers or heterodimers with other P2YRs or with other G-
protein coupled receptors, which increases their diversity further (9). 
 
Two key features of glial P2R is the predominant role for P2Y1R in glial calcium 
signalling and for P2X7R in glial pathology (6, 10). In astrocytes, activation of P2Y1R results in 
an increase in cytosolic Ca2+, often referred to as glial ‘calcium signalling’, which is 
propagated between cells by astroglial release of ATP to activate receptors on neighbouring 
cells in a ‘spillover’ or volume transmission manner (11, 12). Astroglial ATP release in 
physiological signalling may be primarily vesicular and through connexin-43 (Cx43) 
hemichannels, although they can also release ATP through pore-forming P2X7R, pannexin-1 
hemichannels, and volume-regulated anion channels, but the relative importance of the 
different mechanisms in physiological and pathological signalling is unclear (13-16). 
Microglia may also release ATP via Cx43 and vesicles (17, 18), and during ischemia 
oligodendrocytes can release ATP through pannexin hemichannels (19). Nonetheless, ATP 
release under physiological conditions may be principally from astrocytes and appears to act 
on astrocytes and oligodendrocytes predominantly via P2Y1R, which cause a rise in [Ca
2+]i 
through IP3-dependent release of Ca
2+ from intracellular ER stores (11, 12). In microglia, 
UDP-preferring P2Y6R and ADP-preferring P2Y12R have prominent roles in calcium signalling, 
which mediates microglial activation and is heavily dependent on store-operated Ca2+ entry 
(SOCE) (20-22). P2Y12 receptors are also expressed by oligodendrocytes/myelin and have 
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unresolved roles in demyelination (23-25). In the case of P2XR,  heteromeric P2X1/P2X5R 
mediate fast physiological signalling in astrocytes (26, 27), although this is not a universal 
feature of astrocytes (28), and it is not clear that P2XR mediate physiological signalling in 
oligodendrocytes or microglia under non-pathological resting conditions (10). Microglial 
P2X4R are activated by low micromolar ATP concentrations and are important in spinal 
microglia and their involvement in pain (29). The physiological role of P2XR in glia may be in 
doubt, but a universal feature is their expression of P2X7R, which are activated by high levels 
of ATP and mediate pathological responses in all three glial cell types - astrogliosis, 
microglial reactivity, and oligodendrocyte/myelin damage (19, 30-32). 
 
PURINE SIGNALLING IN GLIAL PATHOLOGY 
Multiple P2R are involved in the characteristic responses of glial cells to 
neuropathology (1). Microglia are central to immune and injury responses in the CNS and 
their activation state is carefully controlled by multiple ‘on’ and ‘off’ signals (33). ATP is an 
‘on’ signal and is released by astrocytes and by damaged cells following CNS injury to 
mediate microglial activation (34, 35). There is a prominent role for P2X7R in driving 
microglial activation and proliferation, and P2X7R play a major role in the microglial 
neuroinflammatory response (31, 36, 37). Reactive astrogliosis and glial scar formation is a 
more protracted process and involves prominent roles for both P2X7 and P2Y1R subtypes (9). 
In addition, ATP stimulates the production of pathological levels of pro-inflammatory 
cytokines and prostaglandin E2 (PGE2) by astrocytes, resulting in a double hit and increased 
neuroinflammation and damage (38). The actions of ATP on astroglial and microglial 
purinoceptors results in a vicious cycle in which P2Y1R on reactive astrocytes stimulate 
production of several cytokines/chemokines that activate microglia (39, 40), and P2X7R on 
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activated microglia stimulate secretion of multiple cytokines, including IL-6, TNF-α, and IL-
1, which are key mediators of neurodegeneration, inflammation and pain (41, 42). The 
earliest response of microglia to injury is the rapid ATP-mediated extension of their 
processes to the area of damage and to seal it off from further damage (34, 43). ATP-
induced microglial chemoattraction is principally mediated by P2X4R and P2Y12R (44). P2Y12R 
are expressed by resting microglia and mediate their immediate chemotactic response to 
injury (22), whereas P2X4R are expressed mainly in activated microglia (45) and control their 
fate and survival (46). P2X4R in activated microglia are also central to neuropathic pain (29, 
47, 48). Nerve injury induces increased expression of P2X4R in spinal cord microglia, and 
their activation by ATP triggers calcium influx and the release of brain-derived neurotrophic 
factor (BDNF), which in turn induces neuronal hyperexcitability (49, 50). P2Y6R are also 
upregulated in activated microglia and specifically promote a phagocytic phenotype in 
response to UDP leaked from damaged cells (21, 51). Activation of P2Y6R can reduce the 
permeability of P2X4R, suggesting the interplay between UDP- and ATP-activated receptors 
are important in regulating microglial responses to injury (52). 
 
P2X7R are central to white matter pathology and ATP-mediated loss of 
oligodendrocytes/myelin (53). Oligodendrocytes constitutively express P2X7R and their 
blockade protects against demyelination in experimental autoimmune encephalomyelitis 
(EAE), a model of multiple sclerosis (MS) (54), degeneration following neurotrauma (55), and 
oligodendrocyte loss in ischemia (19). Oligodendrocytes are highly susceptible to 
ischemia/hypoxia and enhanced ATP signaling during oxygen-glucose deprivation (OGD) 
activates oligodendroglial P2X7R and cytosolic Ca
2+ overload, resulting in cell death (19). 
Similarly, the cytotoxic effects of P2X7R in OGD have been demonstrated in microglia (56).  
 7 
In contrast, P2Y1R are protective against ischemic damage in astrocytes and treatment with 
2-MeSADP reduces cytotoxic edema and brain infarction in mice (57-59). However, over-
activation of P2Y1R induces astrocyte reactivity, indicating the ‘Jeckyll and Hyde’ nature of 
purine signalling (9). Oligodendrocytes and their progenitors (OPs) also express P2Y1R (6, 11, 
12, 60-62), and both P2Y1R and P2X7R in OPs are likely to be involved in oligodendrocyte 
regeneration and remyelination, which are prominent features of neuropathology (63-65). 
ATP and its breakdown product adenosine regulate the migration, proliferation and 
differentiation of OPs, acting via A1R, P2Y1R and P2X7R receptors (60, 66, 67). Moreover, 
ATP acting on astroglial P2R triggers their release of leukemia inhibitory factor (LIF) which 
promotes myelination (68). P2Y12R are also enriched in oligodendrocytes/myelin and are 
present in demyelinated lesions, but their precise functions in myelination/demyelination 
are unresolved (23-25). 
 
PURINOCEPTOR SIGNALLING IN THE AGEING BRAIN 
There is a loss of glial function in the ageing brain and glial cells are affected at early 
stages of neurodegenerative processes in Alzheimer’s disease (AD) (69). P2X1/5R-mediated 
calcium signalling in astrocytes was decreased in ageing (27, 70), and there is evidence in 
mouse models of AD of enhanced calcium signalling in astrocytes associated with P2Y1R-
mediated release of ATP from reactive astrocytes (71). Dysregulation of calcium 
homeostasis is a central thesis in AD (72), and increased astroglial calcium signalling is 
observed in animal models of AD and on exposure of astrocytes to β-amyloid (A) (73). Aβ 
increases the amount of ATP released from the astrocytes (74), which would have diverse 
effects on glial cells in AD. Aged microglia express higher levels of P2Y12R and respond to 
extracellular ATP by becoming less dynamic and ramified, opposite to the response of young 
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microglia (75). These studies are consistent with evidence of microglial senescence and 
increased inflammation in the ageing brain (76, 77). In addition, there is up-regulation of 
P2X₇R and increased levels of IL-6, TNF-α, and IL-1 in ageing microglia (78, 79). A vicious 
cycle of increased P2Y1R-mediated release of ATP from astrocytes and increased expression 
of microglial P2X7R would enhance production of cytokines in microglia. 
 
SUMMARY AND CONCLUSIONS 
Purine receptors are central to glial signalling and mediate bipartite effects in glial 
physiology and pathology, and a common theme is that P2X7R and P2Y1R mediate damage 
and repair, respectively. Astrocytes release ATP to act on microglia and oligodendrocytes to 
integrate them within a glial network. In pathology, ATP released from astrocytes and 
damaged cells mediates astrocyte reactivity, microglial activation and 
oligodendrocyte/myelin loss. Moreover, purinergic signalling is likely to play an important 
role in glial dysfunction in the ageing brain and AD, with consequent effects on 
neurodegeneration. Hence glial purine receptors are emerging as drug targets and blockade 
of P2X7R reduces pathology and improves outcome in mouse models of stroke, MS, AD and 
hyperalgesia (54, 80-82). Furthermore, P2X7R drive microglial activation and increase 
production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1, which are key mediators of 
neurodegeneration and oligodendrocyte/myelin damage. In addition, activated microglia 
express P2Y13R and P2Y14R (83-85) and P2Y6R specifically promote a phagocytic microglial 
phenotype, whereas P2Y12R are associated with demyelinating lesions. Overall, purinergic 
receptors are potentially key drug targets for modulating astrocytes and microglia and, 
either directly or indirectly, providing cytoprotection for oligodendrocytes. However, 
purinergic signalling has a ‘Jekyll and Hyde’ nature that is mimicked by glial pathology, 
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whereby they mediate both tissue destruction and repair. It may not be a simple matter of 




The authors would like to acknowledge funders of their research, the University of 
Portsmouth Research Development Fund (AMB, IV), IBBS (AMB, AR), Anatomical Society 




1. Verkhratsky A, Butt, A.M. Glial Neurobiology. Chichester: Wiley; 2007. 
2. Verkhratsky A, Rodriguez JJ, Parpura V. Neurotransmitters and integration in 
neuronal-astroglial networks. Neurochem Res. 2012;37(11):2326-38. 
3. Haroutunian V, Katsel P, Roussos P, Davis KL, Altshuler LL, Bartzokis G. 
Myelination, oligodendrocytes, and serious mental illness. Glia. 2014;62(11):1856-77. 
4. van Wijngaarden P, Franklin RJ. Ageing stem and progenitor cells: implications for 
rejuvenation of the central nervous system. Development. 2013;140(12):2562-75. 
5. Wieghofer P, Knobeloch KP, Prinz M. Genetic targeting of microglia. Glia. 
2015;63(1):1-22. 
6. James G, Butt AM. P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell 
pathology in the central nervous system. Eur J Pharmacol. 2002;447(2-3):247-60. 
7. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. 
Physiol Rev. 2007;87(2):659-797. 
8. Evans RJ. Structural interpretation of P2X receptor mutagenesis studies on drug 
action. Br J Pharmacol. 2010;161(5):961-71. 
9. Franke H, Verkhratsky A, Burnstock G, Illes P. Pathophysiology of astroglial 
purinergic signalling. Purinergic Signal. 2012;8(3):629-57. 
10. Butt AM, Fern RF, Matute C. Neurotransmitter signaling in white matter. Glia. 
2014;62(11):1762-79. 
11. Hamilton N, Vayro S, Kirchhoff F, Verkhratsky A, Robbins J, Gorecki DC, et al. 
Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. 
Glia. 2008;56(7):734-49. 
12. Hamilton N, Vayro S, Wigley R, Butt AM. Axons and astrocytes release ATP and 
glutamate to evoke calcium signals in NG2-glia. Glia. 2010;58(1):66-79. 
13. Suadicani SO, Brosnan CF, Scemes E. P2X7 receptors mediate ATP release and 
amplification of astrocytic intercellular Ca2+ signaling. The Journal of neuroscience : the 
official journal of the Society for Neuroscience. 2006;26(5):1378-85. 
14. Iglesias R, Dahl G, Qiu F, Spray DC, Scemes E. Pannexin 1: the molecular substrate 
of astrocyte "hemichannels". The Journal of neuroscience : the official journal of the Society 
for Neuroscience. 2009;29(21):7092-7. 
15. Haas B, Schipke CG, Peters O, Sohl G, Willecke K, Kettenmann H. Activity-
dependent ATP-waves in the mouse neocortex are independent from astrocytic calcium 
waves. Cereb Cortex. 2006;16(2):237-46. 
16. Mongin AA, Kimelberg HK. ATP potently modulates anion channel-mediated 
excitatory amino acid release from cultured astrocytes. Am J Physiol Cell Physiol. 
2002;283(2):C569-78. 
17. Ma Y, Cao W, Wang L, Jiang J, Nie H, Wang B, et al. Basal CD38/cyclic ADP-
ribose-dependent signaling mediates ATP release and survival of microglia by modulating 
connexin 43 hemichannels. Glia. 2014;62(6):943-55. 
18. Imura Y, Morizawa Y, Komatsu R, Shibata K, Shinozaki Y, Kasai H, et al. Microglia 
release ATP by exocytosis. Glia. 2013;61(8):1320-30. 
19. Domercq M, Perez-Samartin A, Aparicio D, Alberdi E, Pampliega O, Matute C. P2X7 
receptors mediate ischemic damage to oligodendrocytes. Glia. 2010;58(6):730-40. 
20. Michaelis M, Nieswandt B, Stegner D, Eilers J, Kraft R. STIM1, STIM2, and Orai1 
regulate store-operated calcium entry and purinergic activation of microglia. Glia. 
2015;63(4):652-63. 
 11 
21. Koizumi S, Ohsawa K, Inoue K, Kohsaka S. Purinergic receptors in microglia: 
functional modal shifts of microglia mediated by P2 and P1 receptors. Glia. 2013;61(1):47-
54. 
22. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, et al. The 
P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nature 
neuroscience. 2006;9(12):1512-9. 
23. Amadio S, Montilli C, Magliozzi R, Bernardi G, Reynolds R, Volonte C. P2Y12 
receptor protein in cortical gray matter lesions in multiple sclerosis. Cereb Cortex. 
2010;20(6):1263-73. 
24. Amadio S, Parisi C, Montilli C, Carrubba AS, Apolloni S, Volonte C. P2Y(12) 
receptor on the verge of a neuroinflammatory breakdown. Mediators Inflamm. 
2014;2014:975849. 
25. Amadio S, Tramini G, Martorana A, Viscomi MT, Sancesario G, Bernardi G, et al. 
Oligodendrocytes express P2Y12 metabotropic receptor in adult rat brain. Neuroscience. 
2006;141(3):1171-80. 
26. Lalo U, Pankratov Y, Wichert SP, Rossner MJ, North RA, Kirchhoff F, et al. P2X1 
and P2X5 subunits form the functional P2X receptor in mouse cortical astrocytes. The 
Journal of neuroscience : the official journal of the Society for Neuroscience. 
2008;28(21):5473-80. 
27. Palygin O, Lalo U, Verkhratsky A, Pankratov Y. Ionotropic NMDA and P2X1/5 
receptors mediate synaptically induced Ca2+ signalling in cortical astrocytes. Cell Calcium. 
2010;48(4):225-31. 
28. Jabs R, Matthias K, Grote A, Grauer M, Seifert G, Steinhauser C. Lack of P2X 
receptor mediated currents in astrocytes and GluR type glial cells of the hippocampal CA1 
region. Glia. 2007;55(16):1648-55. 
29. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et 
al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. 
Nature. 2003;424(6950):778-83. 
30. Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, et al. 
P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates 
experimental autoimmune encephalomyelitis. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 2007;27(35):9525-33. 
31. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, et al. A role for 
P2X7 in microglial proliferation. J Neurochem. 2006;99(3):745-58. 
32. Bianco F, Colombo A, Saglietti L, Lecca D, Abbracchio MP, Matteoli M, et al. 
Different properties of P2X(7) receptor in hippocampal and cortical astrocytes. Purinergic 
Signal. 2009;5(2):233-40. 
33. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of microglia. 
Physiological reviews. 2011;91(2):461-553. 
34. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid 
microglial response to local brain injury in vivo. Nature neuroscience. 2005;8(6):752-8. 
35. Schipke CG, Boucsein C, Ohlemeyer C, Kirchhoff F, Kettenmann H. Astrocyte Ca2+ 
waves trigger responses in microglial cells in brain slices. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology. 
2002;16(2):255-7. 
36. Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives 
microglial activation and proliferation: a trophic role for P2X7R pore. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2009;29(12):3781-91. 
37. Boucsein C, Zacharias R, Farber K, Pavlovic S, Hanisch UK, Kettenmann H. 
Purinergic receptors on microglial cells: functional expression in acute brain slices and 
 12 
modulation of microglial activation in vitro. The European journal of neuroscience. 
2003;17(11):2267-76. 
38. Fiebich BL, Akter S, Akundi RS. The two-hit hypothesis for neuroinflammation: role 
of exogenous ATP in modulating inflammation in the brain. Front Cell Neurosci. 2014;8:260. 
39. John GR, Simpson JE, Woodroofe MN, Lee SC, Brosnan CF. Extracellular 
nucleotides differentially regulate interleukin-1beta signaling in primary human astrocytes: 
implications for inflammatory gene expression. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 2001;21(12):4134-42. 
40. Kuboyama K, Harada H, Tozaki-Saitoh H, Tsuda M, Ushijima K, Inoue K. Astrocytic 
P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and 
cerebral damage in a rat model of cerebral ischemia. Journal of cerebral blood flow and 
metabolism : official journal of the International Society of Cerebral Blood Flow and 
Metabolism. 2011;31(9):1930-41. 
41. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Purinergic modulation of 
interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp 
Med. 1997;185(3):579-82. 
42. Shieh C-H, Heinrich A, Serchov T, van Calker D, Biber K. P2X7-dependent, but 
differentially regulated release of IL-6, CCL2, and TNF-alpha in cultured mouse microglia. 
Glia. 2014;62(4):592-607. 
43. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314-8. 
44. Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S. Involvement of 
P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 2007;55(6):604-16. 
45. Ulmann L, Levavasseur F, Avignone E, Peyroutou R, Hirbec H, Audinat E, et al. 
Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus. 
Glia. 2013;61(8):1306-19. 
46. Vazquez-Villoldo N, Domercq M, Martin A, Llop J, Gomez-Vallejo V, Matute C. 
P2X4 receptors control the fate and survival of activated microglia. Glia. 2014;62(2):171-84. 
47. Beggs S, Trang T, Salter MW. P2X4R+ microglia drive neuropathic pain. Nature 
neuroscience. 2012;15(8):1068-73. 
48. Tsuda M, Tozaki-Saitoh H, Inoue K. Pain and purinergic signaling. Brain research 
reviews. 2010;63(1-2):222-32. 
49. Trang T, Beggs S, Wan X, Salter MW. P2X4-receptor-mediated synthesis and release 
of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-
activated protein kinase activation. The Journal of neuroscience : the official journal of the 
Society for Neuroscience. 2009;29(11):3518-28. 
50. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, et al. Up-
regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF 
release and neuropathic pain. The Journal of neuroscience : the official journal of the Society 
for Neuroscience. 2008;28(44):11263-8. 
51. Neher JJ, Neniskyte U, Hornik T, Brown GC. Inhibition of UDP/P2Y6 purinergic 
signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo. 
Glia. 2014;62(9):1463-75. 
52. Bernier LP, Ase AR, Boue-Grabot E, Seguela P. Inhibition of P2X4 function by P2Y6 
UDP receptors in microglia. Glia. 2013;61(12):2038-49. 
53. Fern RF, Matute C, Stys PK. White matter injury: Ischemic and nonischemic. Glia. 
2014;62(11):1780-9. 
54. Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, et al. 
P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates 
 13 
experimental autoimmune encephalomyelitis. The Journal of neuroscience : the official 
journal of the Society for Neuroscience. 2007;27(35):9525-33. 
55. Savigni DL, O'Hare Doig RL, Szymanski CR, Bartlett CA, Lozic I, Smith NM, et al. 
Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration 
following neurotrauma. Neuropharmacology. 2013;75:380-90. 
56. Eyo UB, Miner SA, Ahlers KE, Wu L-J, Dailey ME. P2X7 receptor activation 
regulates microglial cell death during oxygen-glucose deprivation. Neuropharmacology. 
2013;73:311-9. 
57. Shinozaki Y, Koizumi S, Ohno Y, Nagao T, Inoue K. Extracellular ATP counteracts 
the ERK1/2-mediated death-promoting signaling cascades in astrocytes. Glia. 
2006;54(6):606-18. 
58. Shinozaki Y, Koizumi S, Ishida S, Sawada J-I, Ohno Y, Inoue K. Cytoprotection 
against oxidative stress-induced damage of astrocytes by extracellular ATP via P2Y1 
receptors. Glia. 2005;49(2):288-300. 
59. Zheng W, Watts LT, Holstein DM, Prajapati SI, Keller C, Grass EH, et al. Purinergic 
receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by 
photothrombosis by energizing glial mitochondria. PloS one. 2010;5(12):e14401. 
60. Agresti C, Meomartini ME, Amadio S, Ambrosini E, Serafini B, Franchini L, et al. 
Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and 
development. Glia. 2005;50(2):132-44. 
61. Weerth SH, Holtzclaw LA, Russell JT. Signaling proteins in raft-like microdomains 
are essential for Ca2+ wave propagation in glial cells. Cell calcium. 2007;41(2):155-67. 
62. James G, Butt AM. P2X and P2Y purinoreceptors mediate ATP-evoked calcium 
signalling in optic nerve glia in situ. Cell Calcium. 2001;30(4):251-9. 
63. Rivers LE, Young KM, Rizzi M, Jamen F, Psachoulia K, Wade A, et al. 
PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons 
in adult mice. Nat Neurosci. 2008;11(12):1392-401. 
64. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. NG2 glia generate 
new oligodendrocytes but few astrocytes in a murine experimental autoimmune 
encephalomyelitis model of demyelinating disease. J Neurosci. 2010;30(48):16383-90. 
65. Young KM, Psachoulia K, Tripathi RB, Dunn SJ, Cossell L, Attwell D, et al. 
Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. 
Neuron. 2013;77(5):873-85. 
66. Othman T, Yan H, Rivkees SA. Oligodendrocytes express functional A1 adenosine 
receptors that stimulate cellular migration. Glia. 2003;44(2):166-72. 
67. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: a neuron-glial 
transmitter promoting myelination in the CNS in response to action potentials. Neuron. 
2002;36(5):855-68. 
68. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes 
promote myelination in response to electrical impulses. Neuron. 2006;49(6):823-32. 
69. Heneka MT, Rodriguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain 
research reviews. 2010;63(1-2):189-211. 
70. Lalo U, Palygin O, North RA, Verkhratsky A, Pankratov Y. Age-dependent 
remodelling of ionotropic signalling in cortical astroglia. Aging cell. 2011;10(3):392-402. 
71. Delekate A, Fuchtemeier M, Schumacher T, Ulbrich C, Foddis M, Petzold GC. 
Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an 
Alzheimer's disease mouse model. Nat Commun. 2014;5:5422. 
72. Verkhratsky A, Parpura V, Pekna M, Pekny M, Sofroniew M. Glia in the 
pathogenesis of neurodegenerative diseases. Biochemical Society transactions. 
2014;42(5):1291-301. 
 14 
73. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. 
Cell calcium. 2003;34(4-5):385-97. 
74. Haughey NJ, Mattson MP. Alzheimer's amyloid beta-peptide enhances ATP/gap 
junction-mediated calcium-wave propagation in astrocytes. Neuromolecular Med. 
2003;3(3):173-80. 
75. Damani MR, Zhao L, Fontainhas AM, Amaral J, Fariss RN, Wong WT. Age-related 
alterations in the dynamic behavior of microglia. Aging cell. 2011;10(2):263-76. 
76. Streit WJ, Braak H, Xue Q-S, Bechmann I. Dystrophic (senescent) rather than 
activated microglial cells are associated with tau pathology and likely precede 
neurodegeneration in Alzheimer's disease. Acta neuropathologica. 2009;118(4):475-85. 
77. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated 
and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39(1):19-34. 
78. Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. Microglia derived from 
aging mice exhibit an altered inflammatory profile. Glia. 2007;55(4):412-24. 
79. Lee HG, Won SM, Gwag BJ, Lee YB. Microglial P2X₇ receptor expression is 
accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse 
model of Alzheimer's disease. Experimental & molecular medicine. 2011;43(1):7-14. 
80. Fulgenzi A, Ticozzi P, Gabel CA, Dell'Antonio G, Quattrini A, Franzone JS, et al. 
Periodate oxidized ATP (oATP) reduces hyperalgesia in mice: involvement of P2X7 
receptors and implications for therapy. Int J Immunopathol Pharmacol. 2008;21(1):61-71. 
81. Arbeloa J, Perez-Samartin A, Gottlieb M, Matute C. P2X7 receptor blockade prevents 
ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiology of 
disease. 2012;45(3):954-61. 
82. Chen X, Hu J, Jiang L, Xu S, Zheng B, Wang C, et al. Brilliant Blue G improves 
cognition in an animal model of Alzheimer's disease and inhibits amyloid-beta-induced loss 
of filopodia and dendrite spines in hippocampal neurons. Neuroscience. 2014;279:94-101. 
83. McIlvain HB, Ma L, Ludwig B, Manners MT, Martone RL, Dunlop J, et al. 
Purinergic receptor-mediated morphological changes in microglia are transient and 
independent from inflammatory cytokine release. Eur J Pharmacol. 2010;643(2-3):202-10. 
84. Kobayashi K, Yamanaka H, Yanamoto F, Okubo M, Noguchi K. Multiple P2Y 
subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury. 
Glia. 2012;60(10):1529-39. 
85. Morioka N, Tokuhara M, Harano S, Nakamura Y, Hisaoka-Nakashima K, Nakata Y. 
The activation of P2Y6 receptor in cultured spinal microglia induces the production of CCL2 
through the MAP kinases-NF-kappaB pathway. Neuropharmacology. 2013;75:116-25. 
86. Carrasquero LM, Delicado EG, Bustillo D, Gutierrez-Martin Y, Artalejo AR, Miras-
Portugal MT. P2X7 and P2Y13 purinergic receptors mediate intracellular calcium responses 
to BzATP in rat cerebellar astrocytes. J Neurochem. 2009;110(3):879-89. 
87. Kinoshita M, Nasu-Tada K, Fujishita K, Sato K, Koizumi S. Secretion of matrix 
metalloproteinase-9 from astrocytes by inhibition of tonic P2Y14-receptor-mediated 
signal(s). Cell Mol Neurobiol. 2013;33(1):47-58. 
 
